Condition: Treatment Resistant Hypertension · Chronic Hemodialysis · Sponsor: University of Erlangen-Nürnberg Medical School
The RDN-HD Study is a prospective, single-center feasibility study. All patients included will undergo endovascular ultrasound-based RDN (no sham group, no blinding). The purpose of the RDN-HD Study is to demonstrate that ultrasound-based RDN is safe in patients with TRH and ESRD hemodialysis and reduces 24-h ambulatory BP.
This description comes directly from the study's public registry record.
Agnes Bosch, MD · +49 9131 8536207 · agnes.bosch@uk-erlangen.de
Roland E. Schmieder, MD · +499131 8536207 · roland.schmieder@uk-erlangen.de
Always discuss trial participation with your own doctor first.
| Friedrich Alexander University Erlangen Nuremberg, Department of Nephrology and Hypertension | Erlangen, Bavaria, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06556407